title: Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel.
abstract: Retinal vein occlusion (RVO) is a common cause of retinal vascular disease, resulting in potentially irreversible loss of vision despite the existence of several therapeutic options. The humanised monoclonal antibody fragment ranibizumab binds to and inhibits vascular endothelial growth factor, a key driver of macular oedema in RVO. In 2010, ranibizumab was approved in the USA for the treatment of macular oedema in RVO and, in 2011, ranibizumab was approved in the European Union for the treatment of visual impairment caused by macular oedema secondary to RVO in branch and central RVO. Ranibizumab provides an additional therapeutic option for this complex disease: an option that was not fully considered during the preparation of current international guidelines. An expert panel was convened to critically evaluate the evidence for treatment with ranibizumab in patients with visual impairment caused by macular oedema secondary to RVO and to develop treatment recommendations, with the aim of assisting physicians to optimise patient treatment.
authors: Augenzentrum Klinik Pallas, Olten, Switzerland Department of Ophthalmology, University of Muenster, Muenster, Germany.
authors: Heinrich
authors: H
authors: Gerding
authors: Institut de la Màcula i de la Retina, Centro Médico Teknon and Barcelona Macula Foundation, Barcelona, Spain.
authors: Jordi
authors: J
authors: Monés
authors: Department of Ophthalmology, Hôpital Lariboisière, Université Paris Diderot-Sorbonne Paris Cité, AP-HP, Paris, France.
authors: Ramin
authors: R
authors: Tadayoni
authors: Department of Ophthalmology, University of Sassari, Sassari, Italy.
authors: Francesco
authors: F
authors: Boscia
authors: St Paul's Eye Unit, Royal Liverpool & Broadgreen University Hospitals NHS Trust, Liverpool, UK.
authors: Ian
authors: I
authors: Pearce
authors: Department of Ophthalmology, General Hospital (AKH), Linz, Austria.
authors: Siegfried
authors: S
authors: Priglinger
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D017410:Practice Guidelines as Topic; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion / Q000188:drug therapy* / Q000503:physiopathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014786:Vision Disorders / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab
keywords: Macula; Retina